Multiple-Dose Pharmacodynamics and Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Subjects

Autor:	Kevin Dykstra, Arthur J. Bergman, Keith Gottesdiener, T Laethem, Daniel M. Bloomfield, P Van Hoydonck, Karen Snyder, M Fallon, Nidal Al-Huniti, K Van Dyck, Ryan Lutz, John A. Wagner, Bo Jin, L M Van Bortel, Maria Gutierrez, Omar F Laterza, M De Smet, Joshua Chen, I.N. Gendrano, Josee Cote, Rajesh Krishna, Cynthia Chavez-Eng, Deborah Hilliard
Rok vydání:	2008
Předmět:	Adult Male Adolescent Apolipoprotein B Dalcetrapib Administration Oral Pharmacology Sensitivity and Specificity Drug Administration Schedule Young Adult chemistry.chemical_compound High-density lipoprotein Double-Blind Method Reference Values Risk Factors Anacetrapib Cholesterylester transfer protein Humans Pharmacology (medical) CETP inhibitor Oxazolidinones Dose-Response Relationship Drug biology Cholesterol Middle Aged Cholesterol Ester Transfer Proteins chemistry biology.protein lipids (amino acids peptides and proteins) Lipoprotein
Zdroj:	Clinical Pharmacology & Therapeutics. 84:679-683
ISSN:	1532-6535 0009-9236
Popis:	Cholesteryl ester transfer protein (CETP) is a plasma protein that catalyzes the heteroexchange of cholesteryl esters from high-density lipoprotein (HDL) and triglycerides to apolipoprotein B–containing lipoproteins, especially very low–density lipoproteins (LDL-C).1,2 Clinical Pharmacology & Therapeutics (2008); 84, 6, 679–683 doi:10.1038/clpt.2008.109
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::056fbe406c24fe12dca69bd8a46d2632 https://doi.org/10.1038/clpt.2008.109 Zobrazit plný text záznamu Plný text